

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 03/072056 A2(51) International Patent Classification⁷: **A61K**

(21) International Application Number: PCT/US03/05874

(22) International Filing Date: 25 February 2003 (25.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/358,700	25 February 2002 (25.02.2002)	US
60/372,921	16 April 2002 (16.04.2002)	US



(71) Applicant (for all designated States except US): **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608-2916 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **XIAO, Linda, Li** [US/US]; 2013 Bartlett Drive, Alameda, CA 94501 (US). **XU, Baoji** [US/US]; 915 Dewing Avenue, Lafayette, CA 94549 (US). **LUO, Jian** [US/US]; 240 Klamath Street,Brisbane, CA 94005 (US). **JOHNSON, Kirk** [US/US]; 147 Brookfield Avenue, Moraga, CA 94556 (US). **FREY, William, H., II** [US/US]; 4800 Centerville Road, Apt. 216, White Bear Lake, MN 55127 (US). **TOZZO, Effie** [FR/US]; 1600 Washington Street, Newton, MA 02465 (US). **DUHL, David** [US/US]; 2720 Camino Lenada, Oakland, CA 94611 (US).(74) Agent: **FRIEDRICHSEN, Bernard**; Foley & Lardner, 150 East Gilman Street, P.O. Box 1497, Madison, WI 53701-1497 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: INTRANASAL ADMINISTRATION OF MC4-R AGONISTS



(57) Abstract: A method for delivering a melanocortin-4 receptor agonist to a mammalian subject, includes administering the melanocortin-4 receptor agonist to a tissue inside the nasal cavity or sinuses of the mammalian subject. In some instances, the melanocortin-4 receptor agonist includes a guanidine functional group.